Cutaneous Melanoma

P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center

Additionally, knockdown of the core risk gene keratin 17 (KRT17) inhibited the invasion and proliferation of B16 cells, demonstrating the role of KRT17 in the progression of SKCM. This study proposed a novel STIRS model and selected the core risk gene KRT17 for functional validation, which had potential as a prognostic tool and a guide for creating personalized therapies for SKCM patients.

P1, N=75, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2027

P1, N=17, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed

P1, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

P1, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

This study establishes a 12-gene signature based on PSRGs, which reliably forecasts clinical prognosis in SKCM. The signature captures features of an immune-activated microenvironment, indicating its dual utility for refining risk stratification and predicting benefit from immunotherapy.

Inhibition of HER2/3 by pan-HER inhibitors blocks cell state plasticity and overcomes chemoresistance in primary MM cell lines and patient-derived xenograft (PDX) models. These findings provide insights into how the tissue of origin determines cancer aggressiveness, highlight the role of mucosal inflammation in driving melanoma stemness and chemoresistance, and advance the identification of effective treatment options currently lacking for patients with MM.

Together, these findings position ACSL4 as a promising prognostic biomarker in melanoma and suggest a potential connection between ferroptosis biology and antitumor immunity. While the study is retrospective and correlative, it provides a strong rationale for prospective validation and mechanistic studies to test whether modulating ACSL4-driven ferroptosis can improve clinical outcomes.

Through the integration of immune deconvolution with circulating immune cell profiles, we derived an ImmuneSignature linked to patient survival. By combining these approaches, we provide a framework for enhancing the prediction of immunotherapy outcomes and offer a novel strategy for identifying therapeutic targets to overcome resistance.

P2, N=8, Active, not recruiting, Diwakar Davar | Recruiting --> Active, not recruiting | N=26 --> 8 | Trial completion date: Jan 2031 --> Jan 2030 | Trial primary completion date: Jan 2028 --> Feb 2026

MelArray detected a notably high number of alterations in the TERT promoter and CDKN2A genes, which were not captured by OFA and are of potential therapeutic relevance. In conclusion, MelArray enables a more comprehensive molecular characterization of cutaneous melanoma compared with a small generic cancer panel and may support more personalized therapeutic decision-making.